Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation - Top-Institutions - MDSpire

Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation

  • By

  • Lilli Leimi

  • Kirsi Jahnukainen

  • Helena Olkinuora

  • Seppo Meri

  • Kim Vettenranta

  • February 17, 2022

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatric Hematology-Oncology
    • Stem Cell Transplantation
    • Vascular Biology

  • #2

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center
    Dana-Farber/Boston Children's Cancer and Blood Disorders Center

    Boston, MA

    Key Differentiators

    • Pediatric Hematology-Oncology
    • Stem Cell Transplantation
    • Endothelial Biology

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematopoietic Stem Cell Transplantation
    • Vascular Complications
    • Pediatric Oncology

  • #4

    Helsinki University Children's Hospital
    Helsinki University Children's Hospital

    Helsinki, Finland

    Key Differentiators

    • Pediatric Hematology
    • Stem Cell Transplantation
    • Vascular Complications

  • #5

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Hematology-Oncology
    • Stem Cell Transplantation
    • Vascular Medicine

Original Source(s)

Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation

  • by Lilli Leimi, Kirsi Jahnukainen, Helena Olkinuora, Seppo Meri, Kim Vettenranta

  • February 17, 2022

Related Content

Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications

Computed tomography-derived sarcopenia, enteral nutritional support, and febrile neutropenia burden in children with acute lymphoblastic leukemia: a retrospective cohort study

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication

  • by

  • May 7, 2026

  • 4 min